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ABSTRACT
Objectives The COVID-19 pandemic has resulted in
widespread morbidity and mortality with the consequences
expected to be felt for many years. Significant variation exists
in the care even of similar patients with COVID-19, including
treatment practices within and between institutions. Outcome
measures vary among clinical trials on the same therapies.
Understanding which therapies are of most value is not
possible unless consensus can be reached on which outcomes
are most important to measure. Furthermore, consensus
on the most important outcomes may enable patients to
monitor and track their care, and may help providers to
improve the care they offer through quality improvement. To
develop a standardised minimum set of outcomes for clinical
care, the International Consortium for Health Outcomes
Measurement (ICHOM) assembled a working group (WG) of 28
volunteers, including health professionals, patients and patient
representatives.
Design A list of outcomes important to patients and
professionals was generated from a systematic review of the
published literature using the MEDLINE database, from review
of outcomes being measured in ongoing clinical trials, from a
survey distributed to patients and patient networks, and from
previously published ICHOM standard sets in other disease
areas. Using an online-modified Delphi process, the WG
selected outcomes of greatest importance.

Strengths and limitations of this study
►► These consensus recommendations were generat-

ed by a large international working group consisting
of all relevant stakeholders with an interest in outcomes of care for patients with COVID-19.
►► The diversity of the working group means that the recommendations included in the standard set are applicable to all settings.
►► The methodology employed in the generation of the
standard set meant that the focus was on outcomes of
relevance to patients throughout and there is a deliberate emphasis on the use of patient-reported outcome
measures in the set.
►► SARS-CoV-2 was discovered just over 1 year ago and so
we cannot yet be certain about the long-term outcomes
of the disease.
►► ICHOM (International Consortium for Health Outcomes
Measurement) standard sets typically undergo an open
review process prior to publication, in which the draft set
is distributed to patients and their representative groups
for feedback; however, this was not possible for this
project given the timeframe.
Results The outcomes considered by the WG to be most
important were selected and categorised into five domains: (1)
functional status and quality of life, (2) mental functioning, (3)
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social functioning, (4) clinical outcomes and (5) symptoms. The WG identified
demographic and clinical variables for use as case-mix risk adjusters. These
included baseline demographics, clinical factors and treatment-related factors.
Conclusion Implementation of these consensus recommendations could help
institutions to monitor, compare and improve the quality and delivery of care
to patients with COVID-19. Their consistent definition and collection could also
broaden the implementation of more patient-centric clinical outcomes research.

INTRODUCTION
SARS-
CoV-
2, the virus responsible for the COVID-
19
pandemic, has infected almost 250 million people and
resulted in the deaths of over 5 million.1 Although knowledge about the acute illness has rapidly expanded, there
is increasing evidence that COVID-19 may have long-term
sequelae, with adverse health outcomes and poor health-
related quality of life lasting far longer than the acute
disease.2
Significant variation exists in the care even of similar
patients with COVID-19, including treatment practices
within and between institutions and countries.3 Furthermore, outcome measures vary among the largest clinical
trials on the same therapies.4 Understanding which therapies are of most value will remain a challenge unless
consensus can be reached on which outcomes are most
important to patients to measure. While survival or indirect measures of patient’s health status, for example,
hospitalisation, the need for mechanical or non-invasive
ventilation, as well as measures of resource utilisation, are
frequently recorded in trials, direct measures of patient-
reported outcomes (PROs) are rarely measured and/or
recorded.5 Furthermore, the follow-up period of many
trials is insufficient to detect some outcomes affecting
patients long after hospital discharge. There is, therefore, a need for a standardised approach to outcome
measurement in COVID-19 to inform clinical practice
and real-world therapeutic research and to allow healthcare providers to monitor outcomes and to identify areas
for quality improvement. A standard set of outcomes, that
is, standardised outcomes, measurement tools and time
points and risk adjustment factors for COVID-19,6 could
help benchmark best practice across institutions, facilitating improvements in care during future outbreaks and
providing value in healthcare. It could also standardise
approaches to global research for patient benefit.
To support the development of a standardised outcome
set in COVID-19 for integration into clinical practice (and
to inform clinical research), the International Consortium
for Health Outcomes Measurement (ICHOM) convened
an international multidisciplinary Working Group (WG)
of experts and patient representatives. As a not-for-profit
organisation, ICHOM has developed 38 standard sets of
value-based outcomes for use in routine clinical practice
in a range of medical conditions, such as coronary artery
disease, stroke and cancer.7 Over 600 organisations have
implemented ICHOM sets including 15 national registries. Standard sets are reviewed and updated annually by
ICHOM.
2

The aim of this paper is to present a standardised
minimum set of outcomes for COVID-19, focusing on the
inclusion of PROs, and case-mix variables, for comparisons across treatment modalities and institutions.

METHODS
Composition of the WG (including patient and public
involvement)
WG members were identified through several avenues. A
rapid review was conducted by the project team in the
project initiation phase to identify relevant patient organisations, measurement initiatives, professional bodies
and publications actively addressing questions relating
to outcome measurement for COVID-19 with a particular focus on patient-centred outcomes. Relevant organisations were contacted and information about the role
of WG members shared both directly as well as through
social media channels. Open recruitment calls were then
held inviting interested individuals to participate in the
WG. A matrix of candidates was composed to facilitate
the representation of diverse geographies, disciplines,
types of expertise, and a balance of specialist interests, for
example, infectious diseases, respiratory disease, mental
health, primary care, intensive care. A shortlist was
created that would represent different matrix cells, and
ICHOM subsequently invited shortlisted individuals to
participate. In addition, individuals or organisations were
given the opportunity to recommend additional candidates for consideration by the ICHOM project team.
Development of the COVID-19 standard set
The WG convened during six teleconferences between
July 2020 and September 2020, following a structured
process similar to that of previous ICHOM WGs. The
development of the standard set involved four phases,
as illustrated in figure 1: defining the scope of the
project; prioritising outcome domains; defining outcome
domains; and evaluating and selecting outcome measures
that would be used to measure these domains, including
clinical data and patient-
reported outcome measures
(PROMs); and selecting and defining case-mix variables.
Identification of potential outcomes, outcome measures and
case-mix variables
The MEDLINE database was used to search for relevant
publications from which potential outcome domains,
outcome measures, PROMs and case-mix variables were
extracted in order to generate a long-list for the WG to
consider. The search strategy used for the MEDLINE
search was:
((‘COVID-19’[Title]) OR (‘novel coronavirus’[Title]))
AND (‘Outcome’[Title]).
Two members of the project team (WHS and NS)
carried out the MEDLINE search using the above strategy
on 1 July 2020, and included papers published in English
language between 1 December 2019 and 1 July 2020.
Seligman WH, et al. BMJ Open 2021;11:e051065. doi:10.1136/bmjopen-2021-051065
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Figure 1

Timeline and data collection process.

Outcomes measured in published trials (apart from
reviews which were excluded in order to generate a list
of primary outcomes from trials) were extracted as well
as outcomes being measured in ongoing trials, as identified by the WHO International Clinical Trials Registry
Platform (ICTRP) database.8 Studies involving specific
populations, such as gender, ethnicity, as well as interventions targeting specific clinical outcomes, for example,
resolution of fever, and laboratory-
based outcome
measures such as inflammatory markers were excluded
as these were deemed by the WG to represent process
measures rather than outcomes that in and of themselves
mattered directly to patients. In addition to extracting the
outcomes, the outcome measures used to measure these
outcomes in the trials included were also extracted. These
outcome measures were discussed after the outcomes
themselves had been selected.
In addition, an electronic survey was distributed at the
start of the project to patients and patient representatives,
through WG members’ healthcare institutions, in line with
their ethical guidelines (see online supplemental file 1). It
was also distributed through the ICHOM newsletter and
social media platforms, as well as to the European Heart
Network and European Lung Foundation patient fora, in
order to identify any additional outcomes that were of particular importance to patients. Finally, outcomes were extracted
from previously published ICHOM standard sets that were of
potential relevance to patients with COVID-19, for example,
patient-reported measures such as health-related quality of
life, and clinical outcomes such as survival.
Seligman WH, et al. BMJ Open 2021;11:e051065. doi:10.1136/bmjopen-2021-051065

Consensus process
WG teleconferences were held every 2 weeks. Following
each teleconference, the project team circulated an electronic survey via the Qualtrics platform to the WG to gather
feedback on each key decision. An online modified Delphi
process was performed over three rounds for the selection of
outcomes, following the RAND/University of California (Los
Angeles) methodology9 and based on a literature review,10 to
achieve consensus on which outcomes should be included.
Inclusion in the standard set required that at least 80% of the
WG voted an item as ‘essential’ (score 7–9 on a 9-point Likert
scale) in each voting round. WG members were given 1 week
to complete each survey. Outcomes were excluded if at least
80% of the WG voted an item as ‘not recommended’ (score
1–3). Inconclusive domains were discussed and revised and
put to a second round of voting. Outcomes that still had not
garnered the required consensus for inclusion were put to a
final third round vote. These three rounds were completed
prior to considering the selection of outcome measures to
capture the outcomes, which did not use the same Delphi
methodology.
Selection of PROMs and case-mix variables
After PROs were chosen for inclusion in the standard set,
corresponding measures were identified from the literature, from tools previously used in other ICHOM standard sets for similar outcome domains, and by outcome
experts in the WG. The original and validation studies of
the instruments were examined in order to evaluate the
psychometric quality, domain coverage, and feasibility of
3
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measurement and implementation. A breakout group
consisting of academics and clinicians with particular
expertise in PRO measures convened to decide on the
most appropriate measures to use.
A different consensus-
gathering process, this time
requiring 70% consensus from the WG for each item, was
used to agree on which measures and case-mix variables
should be recommended in line with the methodology
used in all ICHOM standard sets for this part of the study,
as well as the time points for measuring each outcome.
The 70% consensus level is thought to be sufficient for
the selection of outcome measures and case-mix variables,
whereas a more stringent threshold of 80% or more of
the WG voting an outcome as ‘essential to include’ on
the Likert scale is required in ICHOM methodology for
the selection of the outcomes themselves. The results of
each vote were reviewed by the WG at the subsequent
teleconference. The criteria by which outcome domains
were assessed for inclusion in the set were in accordance
with the concepts of value-based healthcare as described
by Porter.11 Variables to be used as case-mix factors were
assessed on: (1) relevance, (2) independence and (3)
measurement feasibility.

RESULTS
Working Group
ICHOM established a geographically diverse WG covering
a broad range of specialties relevant to COVID-19. The
WG consisted of 28 members, including clinicians, epidemiologists, research scientists, and patients and patient
advocates/representatives from 13 countries across
North and South America, Europe, Africa, the Middle
East, South Asia and Australia (table 1). A project team
(WS, LF, NS, CN and KB) guided the efforts of the WG.
Scope
The outcomes and measures included in the COVID-19
standard set were defined for a target population of all
adults over the age of 18 years with confirmed or highly
suspected SARS-CoV-2 infection, as defined by WHO,12
in primary, secondary or tertiary care settings. Children
under the age of 18 years, as well as asymptomatic individuals with positive diagnostic tests, were excluded from
the set. Different geographical and resource contexts
were considered so that the standard set can be applied
globally.
Outcomes
About 86%, 89% and 82% of WG members participated
in the first, second and third rounds of the modified
Delphi process, respectively. Out of 64 possible outcomes
(see online supplemental file 2) for a list of the sources
of preliminary outcomes) identified through the methodology as described, the WG selected 13 outcomes. There
was significant overlap between the outcomes identified
from the different sources, and during the WG teleconferences, decisions were taken to merge or rename
4

outcomes. The Reference Guide containing the definitions of all outcome domains included, as agreed by the
WG, is published on the ICHOM website at wwwichomorg.
The outcomes were categorised into five major groups:
functional status and quality of life, clinical outcomes,
mental functioning, social functioning and symptoms.
The set of outcomes and measures that were selected are
detailed in table 1.
Each domain has a number of subdomains to capture
what is important to patients. The domain on clinical
outcomes is to be assessed by clinicians. For each of the
remaining domains, the WG identified an appropriate
outcome measure to use. Considering the overlap among
measures, the WG identified the following measures:
Reported Outcomes Measurement Information
Patient-
System (PROMIS) Global 1.2,13 PROMIS Social Isolation
4a14 and FLU-PRO.15
Baseline characteristics and case-mix variables
In addition to the outcomes and outcome measures,
the WG selected important baseline health characteristics to enable comparison between providers (table 2).
These baseline health characteristics include demographic factors, for example, age, sex, race, ethnicity,
level of education, clinical factors, for example, comorbidities and body mass index, and treatment-related
factors, for example, need for ventilation, type of ventilation, duration of ventilation, duration of critical care
admission.
Timeline for follow-up
The WG decided to track patient outcomes over a 3-month
period following the diagnosis or following criteria being
met for highly suspected SARS-CoV-2 infection (figure 2).
The outcome collection period can be extended for a
further 3 months if the patient has not yet fully recovered.
The WG delegated to the treating physicians the decision
whether or not to extend data collection.

DISCUSSION
In this project, an international WG developed a
consensus set of the most important outcomes and
outcome measures in COVID-
19. By measuring and
reporting the same outcomes, and adjusting for the
case-mix variables, providers may be able to improve the
quality of care offered to patients by learning from other
institutions using the same standard set. The standard
set could also benefit patients directly by allowing them
to track their progress over time and seek care when
appropriate through heightened awareness of symptoms
that they may not necessarily realise are problems, for
example, mental health symptoms, or waning productivity. The standard set could also be considered for use
in future respiratory viral pandemics.
This is the first global effort to develop a standardised
minimum set of patient-centred outcomes in COVID-19
for use in clinical practice. While we cannot yet be certain
Seligman WH, et al. BMJ Open 2021;11:e051065. doi:10.1136/bmjopen-2021-051065
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Table 1 Summary of ICHOM C19 standard set of outcomes
Outcome domain

Outcome subdomains

Definition

Outcome measure

Functional status and
quality of life

Health-related quality of life

The perceived quality of an individual’s daily life, assessing
PROMIS Global Health
their health and well-being or lack thereof. A multidimensional 1.2
concept that includes domains related to physical, mental,
emotional and social functioning.

General physical functioning An individual’s ability to perform and/or participate in usual
daily activities required to meet essential needs, fulfil usual
roles, meet usual responsibilities, and maintain health and
well-being.

Mental functioning

Social functioning

Clinical outcomes

Symptoms

PROMIS Global Health
1.2

Vitality/energy

Capacity for work and leisure activities, and efficiency of
FLU-PRO
accomplishment related to a feeling of weariness or tiredness.

Mental health symptoms
and emotional well-being

An individual’s emotional, psychological and social well-being, PROMIS Global Health
including negative feelings and fears, as well as moderate to 1.2
high levels of anxiety or psychological distress.

Cognitive status

An individual’s mental process of knowing, including
awareness, perception, reasoning and judgement.

Clinician measures

Feelings of loneliness and
isolation

An individual’s negative feelings related to the perception of
being alone, disconnected or isolated.

PROMIS Social Isolation
4a

Productivity

An individual’s ability to carry out tasks, actions or participate PROMIS Global Health
in life situations.
1.2

Survival

Any cause of death in a patient with COVID-19.

Clinician measures

Meeting criteria for critical
care admission

Patients whose medical needs cannot be met through
standard ward-based care in an acute hospital, who would
meet criteria for a high dependency or critical care unit.
Patients who meet criteria for critical care admission may not
in fact be admitted to critical care facilities for other reasons,
eg, resource constraints, however, should be included under
this definition.

Clinician measures

Disease course severity

Clinician measures
Mild: No need for hospitalisation
FLU-PRO
Moderate: Hospitalisation without need for non-invasive or
mechanical ventilation
Severe: Received non-invasive and/or mechanical ventilation,
or died; admission to High Dependency Unit (HDU) or
Intensive Care Unit (ICU).

Persisting organ damage

End-organ damage, including the central or peripheral
nervous system, as a result of the COVID-19 infection that
results in impaired function in the individual.

Clinician measures

Duration of hospitalisation

Number of nights spent in hospital being treated for
symptoms related to COVID-19 (irrespective of whether
COVID-19 was the reason for admission or if the patient
developed COVID-19 while in hospital for another reason).
This includes nights spent in hospital on subsequent hospital
admissions during the follow-up period if the individual
being readmitted was being treated for symptoms related to
COVID-19 on that admission.

Clinician measures

Symptoms

A subjective perception suggesting bodily impairment or
malfunction, affecting the individual in a negative manner.

FLU-PRO

ICHOM, International Consortium for Health Outcomes Measurement; PROMIS, Patient-Reported Outcomes Measurement Information System.

about the long-term outcomes of the disease, this work
provides a starting point and there is scope for additional
measures to be included as our understanding of the
disease improves. Other groups, including the WHO Clinical Characterisation and Management Working Group,
have sought to define sets of standardised outcomes in
COVID-
19. This group published a core outcome set
primarily for research use. As such, the outcomes recommended by that group have a clinical and technical
focus and include many indirect measures of patient
outcomes.16 Our project focused on clinical practice,
Seligman WH, et al. BMJ Open 2021;11:e051065. doi:10.1136/bmjopen-2021-051065

however, could also be used to inform real-world clinical
research by incorporating direct patient outcomes, both
in evaluating the course of illness and the effects of therapeutics. This standard set is patient-centric, using PROs
as a key component of the set, and focusing primarily on
outcomes that matter to patients, for example, an individual’s ability to perform and/or participate in usual daily
activities rather than on clinical metrics.
The predominant use of indirect outcomes in clinical
trials of COVID-19 and in monitoring patients’ progress with
the disease runs the risk of missing issues of equal or more
5
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Table 2 Summary of COVID-19 standard set case-mix variables
Case-mix category
Demographic factors

Clinical factors

Treatmentrelated factors

Variable

Measure

Timing

Data source

Age

Year of birth.

Baseline

Patient record

Sex

The patient’s sex at birth.

Race

The biological race of the patient.

Ethnicity

The cultural ethnicity of the patient
that they most closely identify with.

Patient record

Level of education

Highest level of education completed
based on local standard definitions
of education levels.

Patient record

Comorbidities

Prior and current diagnosis of
Baseline
disease or no presence of diagnosis.

Patient/clinician

Body mass index

Height and weight are used to
calculate BMI.

Clinician/healthcare
provider

Need for ventilation

Did the patient require any ventilation Baseline/ updated
monthly
during their hospital admission?

Clinician/healthcare
provider

Type of ventilation

What type of ventilation was
administered?

Duration of ventilation

How long did the patient require
ventilation?

Duration of critical care
admission

How long was the patient’s initial
stay in critical care?

BMI, body mass index.

significance to those suffering with the illness— the disease
burden of symptoms and impaired function that may persist
long after the acute illness. While measuring survival and
clinician-reported outcomes like hospitalisations is essential,
it is equally important to measure PROs which add valuable
information in those who do survive or who are discharged/
remain in hospital. PROs can be used for long-term follow-up
to assess the effect of the disease on a patient’s quality of life,
and to alert treating physicians to the development of complications.17 There is an increasing body of literature suggesting
benefit to patients of various drugs and vaccines against
COVID-19. Validated, standardised PROs that comprehensively assess the symptom experience and patient function in
COVID-19 across multiple domains could also facilitate meta-
analyses and more precise estimates of treatment effects.

Figure 2

6

When considering which PRO measures to use in the set
to measure overall quality of life, the WG felt that a generic
as well as respiratory-specific measure would be most appropriate given the multisystem nature of COVID-
19. One
such universal measurement system is the PROMIS. The
PROMIS Global Health (V.1.2) instrument, which is freely
available, consists of ten global health items that represent
five core PROMIS domains (physical function, pain, fatigue,
emotional distress, social health).18 The majority of PRO
measures included in this set that are not symptoms are
covered within the PROMIS Global Health questionnaire.
One outcome that the WG felt important to include which is
not adequately covered in this instrument is loneliness/isolation, which is captured via the short PROMIS Social Isolation
4a tool.

Follow-up timeline and data collection guidance. PROM, patient-reported outcome measure.
Seligman WH, et al. BMJ Open 2021;11:e051065. doi:10.1136/bmjopen-2021-051065
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In addition to the PROs included in the set, there are a
number of clinical outcomes that the WG felt it essential to
include. The WG felt it important to ensure that the direct
endpoints used took account of the varying practices and
resources that exist across the world. As such, the standard
set is suitable for any primary, secondary or tertiary care
setting in any country. Of note, while many COVID-19 studies
report Intensive Care Unit (ICU) admission as an outcome,
the WG took the view that because ICU provision and therefore the thresholds for admission to ICU vary so significantly depending on the context in which one practices, a
more appropriate outcome measure would be ‘meeting
criteria for ICU admission’ rather than admission itself that
is, explaining the reason for ICU admission and not solely
the event. A similar approach was taken when considering
the issue of non-invasive ventilation, the use of which varied
from being widespread to prohibited based on factors such
as availability of oxygen and concerns around staff infection.
The WG considered that ‘need for non-invasive ventilation,’
while important, could not be classed as an outcome since
the criteria determining ‘need’ varied too much. Instead, this
is included as a case-mix factor so that it can be controlled for
in analyses.
The presence or absence of symptoms was included in the
set on the basis that persistence of symptoms, for example, as
part of ‘long COVID-19’, may be modifiable and may represent a significant disease burden. The WG elected to use a
symptom scale that has been developed and validated for
comprehensively measuring symptoms in viral respiratory
tract diseases—the FLU-PRO scale.15 The scale was developed with patient input and its psychometric properties have
been evaluated in a study with over 500 patients including
those with influenza virus, respiratory syncytial virus, enterovirus, rhinovirus, adenovirus and endemic coronaviruses and
is being used currently in studies of COVID-19.19–21 The scale
was adapted during COVID-19, but in general, can be used to
measure symptoms in any viral respiratory illness.
Consideration was given during WG discussions as to the
appropriate timeline of data collection for patient symptoms.
Although the FLU-PRO asks patients about symptoms in the
previous 24 hours, the WG felt it infeasible to ask patients to
rate their symptoms daily for the entire course of the 3-month
follow-up period. The WG’s recommendation for practical
use was to ask patients to complete the FLU-PRO fortnightly
for the first month and then monthly thereafter, in line with
the timeline for collection of other PRO measures as part of
the ‘PROM package’ depicted in the timeline in figure 2.
An important aspect of this project is the standardisation of
outcome measurement in COVID-19 across differing regions
and healthcare systems. To achieve this, we have published
a comprehensive reference guide summarising the set,
outcome reporting tools, adjustment variables and collection
time points which is freely available at wwwichomorg.
Our approach does have some limitations. The standard set methodology is reliant on the composition of the
WG. Although the WG recruited as diverse members as
was possible given the time constraints, it is possible that a
different WG would have come to different conclusions. Our
Seligman WH, et al. BMJ Open 2021;11:e051065. doi:10.1136/bmjopen-2021-051065

methodology is reliant on the continued involvement of
WG members over several months, and although we did not
experience significant attrition during the various stages of
the consensus-gathering process, nevertheless there remains
the potential for attrition bias to have affected the results of
the rounds of voting. Further, ICHOM standard sets typically undergo an open review process prior to publication in
which the draft set is distributed to patients and their representative groups for feedback. Unfortunately, this was not
possible within the timeframe of this project. The standard
set was developed not as a static document but firmly with
implementation in mind. As such, feasibility of measuring
outcomes was a key concern during the outcome selection
stage and therefore not all outcomes could be included in
the set, despite being recognised by some members of the
WG as important. Furthermore, feasibility of measuring and
global adoption of the set were important determinants of
the symptom scales and PROs that were selected by the WG.
The next stage of this project is to promote implementation of the standard set. Issues to overcome when considering implementing the COVID-19 set include: (1) budget;
(2) availability of clinical leaders to champion the set and
promote its adoption given pressing clinical commitments to
direct patient care in the ongoing pandemic; (3) ensuring
efficient and intuitive means of collecting and storing clinical
data; and (4) ensuring consistent and accurate collection of
PROs. Implementation of the set involves several phases as
described previously.22
CONCLUSION
We have developed a consensus recommendation for a standardised minimum set of outcomes that our WG considered
most important to patients with COVID-19 comprising functional status and quality of life, clinical outcomes, mental
functioning, social functioning and symptoms. The use of
PROs is central to the set and makes the recommendations
particularly relevant. This standard set is targeted for integration into routine clinical practice and research. Use of the
set may enable institutions to monitor, compare, and most
importantly improve the quality of the care they deliver for
patients with COVID-19 as the pandemic unfolds.
Patient and public involvement
Patients and members of the public were involved at the
centre of the work described in this manuscript. Patients
were at the heart of the WG that produced the standard set,
and patients (and their representatives at patient organisations) were directly asked which outcomes they felt were most
important for them at the start of the project. Most of these
outcomes are included in the final list of outcomes selected
by the WG. The patient members of the WG contributed to
the review and final drafts of this manuscript.
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